AU2024204823A1 — Methods of treating fabry patients having renal impairment
Assigned to Amicus Therapeutics Inc · Expires 2024-08-01 · 2y expired
What this patent protects
The present invention relates to migalastat or a salt thereof for use in the treatment of Fabry disease in a patient having an a-galactosidase A protein comprising a HEK assay amenable mutation selected from the group consisting of N34D, N34T, G35V, 1133M, F145S, P146R, L167V, …
USPTO Abstract
The present invention relates to migalastat or a salt thereof for use in the treatment of Fabry disease in a patient having an a-galactosidase A protein comprising a HEK assay amenable mutation selected from the group consisting of N34D, N34T, G35V, 1133M, F145S, P146R, L167V, L180W, R196G, M208R, 1219L, Q221P, N224T, 1242T, Q250R, Q250H, G261S, G261C, 1303F, K326N, F337S, E358Q, and G375E, preferably in a patient having renal impairment.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.